Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.

The American journal of cardiology

Volumn 78, Issue 6 A, 1996, Pages 32-41

  Jacobson, T A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DRUG TOLERANCE; ECONOMICS; FEMALE; HEALTH INSURANCE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RISK FACTOR;

CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG TOLERANCE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RISK FACTORS;

EID: 0030603188     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00660-1     Document Type: Article

References (0)